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Background: Constipation during pregnancy is a common problem. Nowadays only few effective interventions are
published preventing or treating constipation during pregnancy. However, their use is limited due to side-effects.
This uncontrolled intervention study was performed to determine if a mixture of probiotics in the treatment of
constipation during pregnancy is effective.
Methods: Women aged≥ 18 years with functional constipation were included at the Obstetrical outpatient clinic
and midwife practices. Patients received during four weeks a daily dose of EcologicWRelief (Bifidobacterium bifidum
W23, Bifidobacterium lactis W52, Bifidobacterium longum W108, Lactobacillus casei W79, Lactobacillus plantarum W62
and Lactobacillus rhamnosus W71 (total 4*109 CFU)). For all analyses, the non-parametric paired Wilcoxon test was
used. Primary outcome measure was change in defecation frequency. Secondary outcome measures were stool
consistency, sensation of incomplete evacuation, sensation of anorectal obstruction, manual manoeuvres to
facilitate defecation, abdominal pain, adverse effects, presence of reflux episodes and intake of Bisacodyl.
Results: 20 women were included. Defecation frequency significantly increased from 3.1 at baseline to 6.7 in week
four (p < 0.01). Compared to baseline, a significant decrease in 1) sensation of anorectal obstruction from 90.0% to
45.0% (p < 0.01), 2) sensation of incomplete evacuation from 90.0% to 40.0% (p < 0.01), 3) straining during
defecation from 100% to 65% (p = 0.01), 4) episodes of abdominal pain from 60% to 20% (p = 0.01) and 5) the
presence of reflux episodes from 60% to 20% in week four (p = 0.01) was found. Other secondary outcomes did not
decrease significantly. No side effects were reported.
Conclusions: EcologicWRelief is effective in the treatment of constipation during pregnancy. A randomised placebo
controlled trial is required to confirm these data.
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The reported prevalence of constipation in pregnant
women varies between 11-38% and occurs mostly during
the third trimester, although symptoms can also be
present from 12 weeks gestation [1-4]. According to the
ROME III criteria constipation is characterised by strain-
ing during defecation, lumpy or hard stools, sensation of
incomplete evacuation or anorectal obstruction, manual
manoeuvres to facilitate defecation, and/or less than
three defecations per week [5]. At physical examination,* Correspondence: M.M.Tabbers@amc.uva.nl
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distribution, and reproduction in any mediuma palpable faecal mass is often found in the abdomen or
the rectum [6,7].
The pathophysiology underlying functional constipa-
tion is undoubtedly multifactorial and not well under-
stood. Progressively rising progesterone and estrogen
levels have been suggested as cause of constipation dur-
ing pregnancy [3,8,9]. Animal studies have shown that
these female hormones, particularly progesterone, inhibit
gut smooth muscle thereby decreasing esophageal, gas-
tric, and colonic muscle contractility [3,10]. Low fluid
and fibre intake may also play a role. It has been sug-
gested that pregnant women consume less fibres than
recommended for the non-pregnant population, how-
ever this assumption has not yet been confirmed [11,12].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Rome III criteria for functional constipation
I. At least 2 or more of the following criteria:
-Straining during at least 25% of the defecations
-Lumpy or hard stools in at least 25% of the defecations
-Sensation of incomplete evacuation for at least 25% of defecations
-Sensation of anorectal obstruction/blockage for at least 25% of
defecations
-Manual manoeuvres to facilitate defecation for at least 25%
of defecations
-Fewer than three defecations per week
II. Loose stools are rarely present without the use of laxatives
III. Insufficient criteria for irritable bowel syndrome
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lished preventing or treating constipation during preg-
nancy. There is weak evidence showing that increased
fibre intake treating constipation during pregnancy may
improve constipation by increasing the defecation fre-
quency as compared to placebo [13]. A recent published
review evaluating the effectiveness of different laxatives,
concluded that stimulant laxatives may be more effective
than bulk laxatives in improving constipation during
pregnancy by increasing bowel movements and softening
the stools [14]. However, their adverse effects, such as
abdominal pain and diarrhoea, limit their use. In
addition, these studies incorporate low-quality evidence
[14].
Therefore, alternatives that are safe for pregnant women
and the fetus are needed. These alternatives must be in
concordance with the guidelines for treatment of constipa-
tion during pregnancy, stating that non-pharmacological
measures are the first step in treatment [15]. Probiotics
are defined as live micro-organisms which when adminis-
tered in adequate amounts confer a health benefit on the
host [16]. Probiotics probably have at least two modes of
action in improving constipation. Firstly, it is assumed that
dysbiosis in the gut flora plays a role in constipation. Pro-
biotics might improve this dysbiosis [17,18]. Secondly,
probiotics are able to lower pH of the colon by producing
lactic, acetic and other short chain fatty acids. A lower pH
enhances colonic peristalsis and subsequently decreases
colonic transit time [17,18]. Probiotics might also be ef-
fective in the treatment of constipated pregnant women.
Probiotics have shown to be safe for mother and fetus dur-
ing pregnancy. Several randomised controlled trials to in-
vestigate the safety of probiotics during pregnancy did not
report an increase in adverse events related to probiotics
[17-23]. Furthermore, current data suggest that probiotic
supplementation is rarely systemically absorbed when
used by healthy individuals [23].
Few studies on the effectiveness of probiotics in consti-
pated adults have been performed. A recent review found
that strains of lactobacilli and bifidobacteria increased
the defecation frequency and improved stool consistency
in constipated men and women [24]. In addition, a ran-
domised controlled trial in constipated elderly using
Lactobacillus rhamnosus and Propionibacterium freuden-
reichii showed positive results in defecation frequency
[25]. Other randomised controlled trials in constipated
adults also show significant effects on defecation fre-
quency and stool consistency [26-28]. Bekkali at al. [29]
described the effectiveness of EcologicWRelief (a mixture
of Bifidobacterium bifidum W23, Bifidobacterium lactis
W52, Bifidobacterium longum W108, Lactobacillus casei
W79, Lactobacillus plantarum W62 and Lactobacillus
rhamnosus W71) in constipated children. Based on the
positive results of probiotics in constipated children andthe adverse effects of existing treatment options for con-
stipation during pregnancy, we hypothesized similar
positive effects of this probiotic mixture in constipated
pregnant women not responding to conventional treat-
ments. Therefore we performed a pilot study to deter-




Pregnant women with constipation aged≥18 years, who
are between 12 and 34 weeks into their pregnancy were eli-
gible. Our goal was to include 20 pregnant women. They
were included at the Obstetrical outpatient clinic of the
Academic Medical Centre in Amsterdam and 28 partici-
pating midwife practices in the municipal of Amsterdam.
Women were included when they were suffering from
functional constipation according to the Rome III criteria
[5] (Table 1). Criteria had to be fulfilled for at least two
weeks with symptom onset during pregnancy. Women
were excluded if they had been treated for constipation less
than one week before the start of the study. Other exclu-
sion criteria were: a diagnosis of mental retardation or
metabolic disease (hypothyroidism), Hirschsprung’s dis-
ease, spinal anomalies, anorectal pathology, inflammatory
bowel disease, previous gastrointestinal surgery, the use of
fermented dairy products containing probiotics two weeks
prior to the study. All participants signed an informed con-
sent. This pilot was approved by the medical ethical com-
mittee of the Academic Medical Centre, Amsterdam.
Study design
This pilot study was an uncontrolled intervention study
intended to evaluate feasibility, adverse effects and effect
size of the probiotics in constipated pregnant women. All
subjects received four grams of EcologicWRelief containing
(4*109 CFU) of the probiotic strains Bifidobacterium bifi-
dum W23, Bifidobacterium lactis W52, Bifidobacterium
longum W108, Lactobacillus casei W79, Lactobacillus
Table 2 Baseline patient characteristics: median (SD),
n = 20
Age in years 29.5 (5.3)
Gravidity 1.0 (1.3)
Parity 0.0 (0.4)
Number of weeks pregnant 19.5 (7.5)
Stool frequency per week 3.0 (1.6)
Straining during defecation 100.0%
Hard stools 90.0%
Sensation of incomplete evacuation 90.0%
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daily for four weeks. Bekkali et al. [29] showed four
weeks is an appropriate period to observe short-term
(adverse) effects of probiotics. Other components of
this powder were very small amounts of rice starch,
maltodextrins, inulin, potassium chloride, magnesium
sulphate, fructo-oligosaccharides (FOS) and manganese
sulphate. Patients were instructed to mix the powder
in one glass (200 mL) of lukewarm water in the morn-
ing and ingest this solution before breakfast.
At intake, all participants completed a non-validated
questionnaire created by the authors about their
defecation frequency, consistency of stools, sensation of
incomplete evacuation or anorectal obstruction and
manual manoeuvres regarding the week prior to the in-
take. Also gastro-intestinal symptoms such as abdominal
pain and reflux episodes were evaluated. Furthermore, a
general medical history and the use of medication were
listed. Information and education about functional con-
stipation was given to all patients. Before the start of the
probiotic treatment, all subjects received one rectal
enema (Microlax) once daily for three days in order to
achieve rectal disimpaction to create a homogeneous
study group.
If a subject did not defecate for three days during the
study period, a stimulant laxative (Bisacodyl 5 mg, orally
or rectally) was prescribed on the fourth day. During the
study, women were not allowed to consume any fermen-
ted dairy products containing probiotics or any laxatives,
except for the rescue medication Bisacodyl. Participants
were asked not to change their daily dietary intake, like
fluids and fibres, during the study period.
During the treatment phase intake of study medica-
tion, defecation frequency, consistency of stools, pain
during defecation, frequency of episodes of faecal incon-
tinence, sensation of incomplete evacuation or anorectal
obstruction and possible adverse effects such as abdom-
inal pain, diarrhoea and bad taste were recorded daily in
a defecation diary by the pregnant women. This diary
contained similar questions as the questionnaire used at
baseline. After four weeks, the study medication was
stopped and a follow-up appointment was scheduled
two weeks later.
Clinical evaluation, frequency of adverse effects and
compliance were evaluated at baseline and at two, four
and six weeks after starting probiotic usage.
Outcome measures
The primary outcome measure was the change in
defecation frequency after four weeks of probiotic use
compared to baseline. Secondary outcome measures
were stool consistency, sensation of incomplete evacu-
ation, sensation of anorectal obstruction, manual man-
oeuvres to facilitate defecation, abdominal pain, adverseeffects (bad taste and diarrhoea), presence of reflux epi-
sodes and frequency of intake of Bisacodyl.Analysis
Baseline characteristics, adverse effects and Bisacodyl
use were documented in a descriptive way. For change
in defecation frequency and for the comparison of all
secondary outcome measures between baseline and the
evaluation time points, the non-parametric paired Wil-
coxon test was used. Data at baseline were weekly out-
comes, therefore data from the defecation diary were
summarized into weekly outcomes in order to be able to
compare. Statistical significance for the primary outcome
measure and all secondary outcome measures was
defined as p ≤ 0.05. All analyses were performed in SPSS
(version 17.0).Results
Between October 2008 and May 2011, 20 women were
enrolled into this pilot study and all participants com-
pleted the study. The baseline characteristics are sum-
marized in Table 2.
The median defecation frequency per week signifi-
cantly increased from 3.0 at baseline to 7.0 in week two
(p < 0.01) and 6.0 in week four (p < 0.01) (Figure 1). As
shown in Table 3, all secondary outcome measures, ex-
cept for hard stools and manual manoeuvres, improved
significantly after two weeks and these results sustained
until the end of the treatment period.
Rescue medication, Bisacodyl, was used by two
women. One patient used Bisacodyl once in week one,
five times in week two and daily in week three and week
four. The second woman used Bisacodyl only once in
week four. No side effects were reported. Based on the
diary, the compliance was 100%.
Figure 1 Primary outcome: change in defecation frequency (n=20), p < 0.01.
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To our knowledge, this is the first study investigating
the use of probiotics in constipated pregnant women. A
significant increase in defecation frequency was
observed. Furthermore, the presence of sensation of in-
complete evacuation, sensation of anorectal obstruction,
straining during defecation, abdominal pain and reflux
episodes also improved significantly with the use of this
probiotic mixture. No adverse effects were reported dur-
ing the study.
The improvement of all important defecation char-
acteristics in constipated pregnant women are in ac-
cordance with the results found by Bekkali et al. in
20 children with constipation using the same mixture
of probiotics. The latter study reported a significant
increase in bowel movements, a decrease in fecal incon-
tinence episodes and a decrease in abdominal pain [29].
Our results are also in line with a recent review on the
efficacy of probiotics by Chmielewska et al. [24]. They
found that Bifidobacterium lactis DN-173 010, Lactoba-
cillus casei Shirota and Escheria Coli Nissle 1917, used
in different randomised controlled trials in constipated
men and non-pregnant women, increased the defecation
frequency and improved stool consistency [24]. A recentTable 3 Secondary outcome measures with p-values (n = 20)
Outcome Baseline W
Straining during defecation 100.0% 7
Hard stools 90.0% 6
Sensation of incomplete evacuation 90.0% 3
Sensation of anorectal obstruction 90.0% 4
Manual manoeuvres 10.0% 5
Abdominal pain 60.0% 3
Reflux episodes 60.0% 4double-blind randomised placebo controlled trial in
otherwise healthy constipated adults using different
strains of lactobacilli and bifidobacteria also showed an
increase in bowel movements, positive effects on stool
consistency and on discomfort items such as abdominal
bloating and anal itching [26]. A randomised trial in
constipated elderly using a mixture of probiotics includ-
ing Lactobacillus rhamnosus and Propionibacterium
freudenreichii showed positive results with respect to
defecation frequency as well [25]. It should be noted that
the composition of the strains of probiotics used in the
described studies is different and effects might therefore
be strain- or product-specific. For this reason, one
should be careful comparing these studies. Studies com-
paring the effects of these different strains are not
available.
It has been suggested that the findings in men and
non-pregnant women, elderly and children are not dir-
ectly applicable to constipated pregnant women, be-
cause of differences in pathophysiology. The main
difference is the changed hormone levels during preg-
nancy (e.g. progesterone) [3,8,9,11,12]. Our study was
designed as a pilot study on the use of probiotics and
not to elucidate the effect of probiotics on theeek 2 Week 4 P-value (week 4 – week 0)
0.0% 65.0% P= 0.01
5.0% 65.0% P= 0.10
5.0% 40.0% P< 0.01
0.0% 45.0% P< 0.01
.0% 5.0% P= 0.56
0.0% 20.0% P= 0.01
5.0% 20.0% P= 0.01
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tion. So, this hypothesis remains unresolved. The fact
that our results are in line with published results in
non-pregnant women, suggests that at least some of
the pathophysiological mechanisms are independent of
pregnancy and comparable to non-pregnancy, like low
fibre and low fluid intake.
Clinical relevance
Pregnant women may experience constipation for the
first time during pregnancy or their existing constipation
symptoms increase in severity during pregnancy [30].
Besides discomfort of constipation symptoms, straining
during defecating can damage the pudendal nerve and
impair the supportive function of the pelvic floor muscu-
lature [31,32]. Furthermore disturbed defecation can re-
sult in the development of uterovaginal prolapse [33].
Therefore it is important to recognize the symptoms of
constipation and treat these complaints in an early phase
of pregnancy. In clinical practice, laxatives and fibres are
frequently used. Laxatives like Lactulose and Bisacodyl
have proven to be safe for mother and fetus and should
therefore be considered in the treatment of constipation
during pregnancy [14]. Unfortunately, their side effects,
such as abdominal pain and diarrhoea, limit their use
[14]. Besides, changing dietary habits is difficult to ac-
complish and laxatives are considered pharmacological
treatment and are not recommended as the first step in
treatment of constipated pregnant women [15]. Poly-
ethylene glycol (PEG)-based laxatives technically meet
the criteria for the ideal treatment in constipation [34].
However, present data are insufficient to exclude any ad-
verse effects on the foetus [34]. Probiotics are non-
pharmacological and widely used in an otherwise healthy
population. Based on the results of our study, probiotics
could be of additional value in the treatment of consti-
pation in clinical practice in pregnant women.
This study was designed as a pilot study with inherent
limitations. Due to the lack of a control group, an import-
ant placebo effect of probiotics cannot be excluded. Besides
that, because of the uncontrolled design, there is no infor-
mation available on the natural course of constipation dur-
ing pregnancy. However, since this study shows positive
results on constipation symptoms, it is worthwhile to per-
form a large randomised trial to unravel the efficacy of this
mixture probiotic strains in constipated pregnant women.
It was difficult to include the 20 patients needed for
this pilot study. We experienced that underreporting of
defecation problems is a major issue due to a taboo
among pregnant women, midwives and doctors to dis-
cuss defecation patterns. In addition, most pregnant
women who refused participation to our study, did not
experience constipation as a medical problem during
their pregnancy, but believed constipation is part ofbeing pregnant. Another frequently heard reason for not
participating in the study is that pregnant women ex-
perience their pregnancy as a stressful time and do not
want to worsen this experience by participating in scien-
tific research.
Another limitation of this study is the non-validated
questionnaire used at baseline, which could have caused
recall bias resulting in possible underreporting of
defecation frequency per week and other defecation
related parameters prior to the study. This could partly
explain the initial increase in defecation frequency as
shown in Figure 1. But we assume the main effect
observed in this study could be contributed to the mix-
ture of probiotics. Besides, Pamuk et al. showed that the
recall bias in questionnaires used to report defecation
pattern is negligibly low [35].
The powder used in this study contains very small
amounts of inuline and fructooligosaccharides (FOS).
These inuline-type prebiotics are considered bifidogenic,
stimulating the growth of Bifidobacterium species in the
gut [36]. Studies on the effect of these prebiotics on
defecation frequency and consistency of stools, show
conflicting results [37]. However, it cannot be excluded
that small amounts of prebiotics used in this study do
have an additive effect on our results in the improve-
ment of constipation symptoms. Future studies should
address this issue.
Conclusion
This small pilot study showed that the multispecies pro-
biotic mixture EcologicWRelief seems to be safe and pos-
sibly effective in constipation during pregnancy. A large
placebo-controlled randomised trial is now required to
confirm these data.
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